| DOI: 10.29090/psa.2026.01.25.8760 | Pharm Sci Asia 2026; 53(1), 102-111 |
Cost-effectiveness analysis of TB-R (Tuberculosis Reminder) application implementation for pulmonary tuberculosis patient management in hospitals across underdeveloped regions of IndonesiaYusransyah Yusransyah1, Didik Setiawan2, Abdillah Mursyid1, Mohamad Subchan3, Sofi N. Stiani1, Baha Udin1
1 Pharmacy Study Program, Sekolah Tinggi Ilmu Kesehatan Salsabila Serang, Serang, 42211, Banten, Indonesia
2
Department of Social and Administrative Pharmacy, Faculty of Pharmacy, Universitas Muhammadiyah Purwokerto, Banyumas, Central Java, Indonesia
3
Information Systems Study Program, Faculty of Engineering and Computer Science, Universitas Muhammadiyah Banten, 15720, Indonesia
Pulmonary tuberculosis (TB) remains a major health problem in Indonesia. Patient adherence to long-term therapy is a challenge, impacting the effectiveness and cost of healthcare. Technological innovations such as the Tuberculosis Reminder (TB-R) application have the potential to support more effective and efficient treatment. This study evaluates the cost-effectiveness of implementing the TB-R application on the management of pulmonary TB patients in Indonesia. This study was conducted at a hospital in a disadvantaged district of Indonesia (Pandeglang). A quasi-experimental study was conducted in a hospital in a disadvantaged area, with 66 pulmonary TB patients divided into an intervention group (using the TB-R application) and a control group (without the TB-R application). Data were collected through medical records, AFB smear examinations, radiology, and treatment cost summaries. Cost-effectiveness analysis was calculated using the Incremental Cost-Effectiveness Ratio (ICER), and sensitivity analysis was performed. Therapeutic effectiveness, defined as treatment success based on negative conversion of Acid-Fast Bacillus (AFB) smear and improvement in chest radiology findings at the end of the intervention period, was higher in the TB-R group (63.6%) compared with the control group (30.3%). The total treatment cost per patient was also lower (IDR 698,182 vs. IDR 741,818). The ICER value of -IDR 130,909 indicates that the TB-R group was dominant (more effective and less expensive) than the control group. Sensitivity analysis showed that the parameters influencing the ICER value were the results of the Acid-Fast Bacillus (AFB) and radiology examinations. TB-R has been proven to be a cost-effective intervention in the treatment of pulmonary TB, with higher clinical effectiveness and cost-efficiency.
Keyword:
Cost-effectiveness; Digital application; Pulmonary tuberculosis
Download full paper (PDF File size: 510.14 KB.)
|
